End-of-life decisions and opinions: Results of E.L.D.Y.-CA.RE study carried out at Veneto Institute of Oncology, Italy [0.03%]
临终决策与观点:意大利威尼斯肿瘤研究所开展的E.L.D.Y.-CA.RE研究结果
Valter Giantin,Chiara Curreri,Caterina Ugolini et al.
Valter Giantin et al.
Background: Issues related to end-of-life decisions (ELDs) generate impassioned debates in society. Our study aimed at investigating attitudes in care of cancer patients at the end-of-life (EOL); ascertaining the opinion ...
Quality indicators in identification and care of patients with genetic predisposition to cancer: An AIFET proposal [0.03%]
遗传性癌症患者识别和照护的质量指标:AIFET建议
Andrea Remo,Maria Grazia Tibiletti,Giovan Battista Rossi et al.
Andrea Remo et al.
Hereditary cancer genetics is increasingly recognized as an integral component of cancer care, contributing to treatment, early detection, and risk reduction strategies for patients and their relatives. In this context, several hereditary c...
Driver vs. passenger: Primary resistance to larotrectinib in synovial sarcoma harboring concurrent SS18 rearrangement and PDE3A-NTRK2 fusion [0.03%]
司机与乘客:同时存在SS18重排和PDE3A-NTRK2融合的滑膜肉瘤对larotrectinib出现主要耐药性
Rashad Ismayilov,Buge Oz,Arzu Oguz et al.
Rashad Ismayilov et al.
Background: Synovial sarcoma (SS) is molecularly defined by the pathognomonic SS18::SSX fusion, a master epigenetic driver. While NTRK gene fusions are high-priority tissue-agnostic targets for TRK inhibitors like larotre...
Beyond the calendar: A narrative review on chronobiological drivers of prognosis in resectable NSCLC [0.03%]
超越日历:关于可切除NSCLC预后中昼夜节律驱动因素的叙述性综述
Giovanni Leuzzi,Pamela Minicozzi,Paolo Verderio et al.
Giovanni Leuzzi et al.
For decades, the surgical management of non-small cell lung cancer (NSCLC) has been predominantly guided by anatomical staging. However, this traditional approach often overlooks the "fourth dimension" of cancer biology: time. This narrativ...
Challenging the cornerstone: Toward risk-adapted follow-up in early breast cancer [0.03%]
挑战传统观念:早期乳腺癌的个体化随访策略
Catia Angiolini,Antonella Ferro,Luca Moscetti
Catia Angiolini
The follow up in early breast cancer represented a major challenging in oncology practice. Current guidelines are supported by evidence demonstrating no benefit of intensive surveillance.Despite evidence, many oncologists still practice a m...
Assessing in house comprehensive genomic profiling by liquid biopsy for NSCLC patients [0.03%]
肺癌患者采用液态活检技术进行二代测序的回顾性分析
Andrea Vingiani,Alberta Piccolo,Adele Busico et al.
Andrea Vingiani et al.
Purpose: Liquid biopsy has emerged as a valuable tool for detecting therapeutic targets and resistance mechanisms. This study evaluated the analytical performance and clinical utility of TruSight Oncology 500 ctDNA (TSO50...
End-of-life care: A retrospective study comparing sarcoma and patients with carcinoma [0.03%]
终末期癌症患者的护理回顾性研究——肉瘤与腺癌患者的比较
Luca Zambelli,Giacomo Massa,Francesca Ricchini et al.
Luca Zambelli et al.
Background: Soft tissue and bone sarcomas may carry a considerable symptom burden, which typically worsens in the final weeks of life. To help clarify personalized palliative care needs, we investigated discrepancies in e...
A practical framework of preoperative imaging for non-small cell lung cancer: Thoracic surgeons' expectations from radiologists [0.03%]
非小细胞肺癌的术前影像检查实用框架:胸外科医师对放射科医师的期待
Ulas Kumbasar,Gamze Durhan
Ulas Kumbasar
Accurate preoperative imaging is essential for determining operability, guiding surgical planning, and optimizing outcomes in the treatment of non-small cell lung cancer (NSCLC). This paper outlines thoracic surgeons' expectations from radi...
Multiparametric whole-body magnetic resonance imaging in breast cancer management: A prospective study [0.03%]
乳腺癌治疗中多参数全身磁共振成像的前瞻性研究
Michela Palleschi,Filippo Merloni,Andrea Prochowski Iamurri et al.
Michela Palleschi et al.
Multiparametric Whole-Body Magnetic Resonance Imaging (WB-MRI) may enhance bone metastasis detection in metastatic breast cancer (mBC) patients. We report preliminary results from a prospective clinical trial investigating WB-MRI utility in...
Alectinib and gastrointestinal perforation in ALK-rearranged non-small cell lung cancer: A case series [0.03%]
Alecitinib治疗间变性淋巴瘤激酶重排非小细胞肺癌的胃肠穿孔不良反应的病例系列分析
Margherita Piccinelli,Raffaele Squitieri,Rebecca Romanò et al.
Margherita Piccinelli et al.
Background: Alectinib, a second-generation ALK inhibitor, is used in first-line and adjuvant treatment for ALK-rearranged NSCLC, and has proven to be both effective and well tolerated. Gastrointestinal (GI) perforation is...